From January 1, 2024 to March 31, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 17,998,609 shares, representing 13.25% for $750.03 million under the buyback announced on December 9, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.55 USD | +1.36% |
|
+4.14% | +39.48% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.48% | 6.56B | |
+15.19% | 121B | |
+19.91% | 114B | |
-19.80% | 20.43B | |
-16.45% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.